Dig Liver Dis: Increased levels of neotrexate are associated with chronic liver failure and mortality in patients with cirrhosis.

Macrophage actification plays a central role in liver and systemic inflammation and is involved in the pathogenesis of acute and chronic liver failure (ACLF).
then there is a biomarker, the new butterfly, which reflects the activity of the whole macrophage, which increases significantly in infectious, cardiovascular, neurodegenerative, autoimmune diseases.
therefore, the purpose of this study was to investigate the level of new butterfly methotrexate in patients with acute off-claim period (AD) of cirrhosis and to assess their relationship to ACLF and prognosis.
the study, a prospective cohort study, the researchers included 205 adult subjects hospitalized for acute disparagency (AD) from cirrhosis.
21 healthy subjects and 89 patients with stable cirrhosis were compared.
higher levels of new butterfly in AD than stable cirrhosis and healthy controls (p .lt;0.001).
ACLF is independently associated with higher levels of new butterfly (OR 1.015, 95% CI 1.002-1.028, p ??0.025).
In the multi-Cox regression analysis, the new butterfly level (HR - 1.002, IC 95% 1.000 - 1.004, p ?? - 0.041), Child-Pugh C and ACLF are predicted indicators of 30-day survival.
In ACLF patients, the Kaplan-Meier survival probability was 71.4% in patients with new butterfly sl;25 nmol/ L, and 31.0% in patients with new butterfly s 25 nmol/ L (p .lt;0.001).
: New levels of neotreating in patients with acute loss of recovery from cirrhosis increased significantly, so the authors conclude: In patients hospitalized with AD of cirrhosis, higher circulatory neotrexate is associated with ACLF.
the new butterfly level is also an independent predictor of high short-term mortality.
.